ArticleNPJ breast cancer2022

HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.

Federica Miglietta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.